Mark Hahn - Oct 20, 2023 Form 4 Insider Report for Verona Pharma plc (VRNA)

Role
Chief Financial Officer
Signature
/s/ Claire Poll, Attorney-in-fact for Mark Hahn
Stock symbol
VRNA
Transactions as of
Oct 20, 2023
Transactions value $
$0
Form type
4
Date filed
10/24/2023, 04:05 PM
Previous filing
Aug 7, 2023
Next filing
Nov 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Award $0 +800K +5.15% $0.00 16.3M Oct 20, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter.
F3 Consists of (i) 6,711,816 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 838,977 ADSs); and (ii) 9,609,432 Ordinary Shares underlying 1,201,179 ADSs.